Early detection of radiation therapy response in non-Hodgkin's lymphoma xenografts by in vivo1H magnetic resonance spectroscopy and imaging

NMR in Biomedicine

Volumn 23, Issue 6, 2010, Pages 624-632

  Lee, Seung Cheol ^a   Poptani, Harish ^a   Pickup, Stephen ^a   Jenkins, W Timothy ^a   Kim, Sungheon ^b   Koch, Cameron J ^a   Delikatny, E James ^a   Glickson, Jerry D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Human tumor xenograft; Non Hodgkin's lymphoma; Nuclear magnetic resonance; Proton nmr; Radiation therapy; Response marker

Indexed keywords

BIOLOGICAL MATERIALS; FATTY ACIDS; LIPIDS; MAGNETIC MATERIALS; MAGNETIC RESONANCE SPECTROSCOPY; NUCLEAR MAGNETIC RESONANCE; ONCOLOGY; PROTONS; QUANTUM THEORY; RADIOTHERAPY; RESONANCE; SURFACE DIFFUSION; TUMORS;

ACQUISITION MODES; APPARENT DIFFUSION COEFFICIENT; DIFFUSE LARGE B-CELL LYMPHOMA; DIFFUSION WEIGHTED IMAGING; EARLY DETECTION; HADAMARD; HUMAN TUMORS; IN-VIVO; MULTIPLE-QUANTUM COHERENCES; NON-HODGKIN'S LYMPHOMA; NUDE MICE; POLYUNSATURATED FATTY ACIDS; PROTON NMR; RADIATION THERAPY; RADIATION TREATMENTS; RELATIVE SENSITIVITY; TUMOR GROWTH; TUMOR VOLUMES;

RADIATION;

CARBENE; CHOLINE; LACTIC ACID; LIPID; POLYUNSATURATED FATTY ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; EARLY DIAGNOSIS; GROWTH; IN VIVO STUDY; LARGE CELL LYMPHOMA; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RADIATION DOSE; SENSITIVITY ANALYSIS; XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; HUMAN; LIPID METABOLISM; LYMPHOMA, NON-HODGKIN; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUDE MOUSE; PATHOLOGY; PROCEDURES;

ANIMALS; CHOLINE; HUMANS; LACTIC ACID; LIPID METABOLISM; LYMPHOMA, NON-HODGKIN; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS;

EID: 77955097893     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1505     Document Type: Article

References (53)

1. American Cancer Society. Cancer Facts and Figures 2008. American Cancer Society: Atlanta, 2008.
2. Gustavsson A, Osterman B, Cavallin-Stahl E. A systematic overview of radiation therapy effects in non-Hodgkin's lymphoma. Acta. Oncol. 2003; 42: 605-619.
3. Moffat BA, Chenevert TL, Lawrence TS, Meyer CR, Johnson TD, Dong Q, Tsien C, Mukherji S, Quint DJ, Gebarski SS, Robertson PL, Junck LR, Rehemtulla A, Ross BD. Functional diffusion map: A noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc. Nat. Acad. Sci. 2005; 102: 5524-5529.
4. Katz-Brull R, Lavin PT, Lenkinski RE. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J. Natl. Cancer Inst. 2002; 94: 1197-1203.
5. Fuchsjäger M, Akin O, Shukla-Dave A, Pucar D, Hricak H. The role of MRI and MRSI in diagnosis, treatment selection, and post-treatment follow-up for prostate cancer. Clin. Adv. Hematol. Oncol. 2009; 7: 193-202.
6. Kumar R, Maillard I, Schuster SJ, Alavi A. Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas. Radiol. Clin North. Am. 2004; 42: 1083-1100.
7. Ng TC, Vijayakumar S, Majors AW, Thomas FJ, Meaney TF, Baldwin NJ. Response of a non-Hodgkin lymphoma to 60Co therapy monitored by 31P MRS in situ. Int. J. Radiat. Oncol. Biol. Phys. 1987; 13: 1545-1551.
8. Bryant DJ, Bydder GM, Case HA, Collins AG, Cox IJ, Makepeace A, Pennock JM. Use of phosphorus-31 MR spectroscopy to monitor response to chemotherapy in non-Hodgkin lymphoma. J. Comput. Assist. Tomogr. 1988; 12: 770-774.
9. Smith SR, Martin PA, Davies JM, Edwards RH, Stevens AN. The assessment of treatment response in non-Hodgkin's lymphoma by image guided 31P magnetic resonance spectroscopy. Br. J. Cancer. 1990; 61: 485-490.
10. Smith SR, Martin PA, Edwards RH. Tumour pH and response to chemotherapy: an in vivo 31P magnetic resonance spectroscopy study in non-Hodgkin's lymphoma. Br. J. Radiol. 1991; 64: 923-928.
11. Dixon RM, Angus PW, Rajagopalan B, Radda GK. Abnormal phosphomonoester signals in 31P MR spectra from patients with hepatic lymphoma. A possible marker of liver infiltration and response to chemotherapy. Br. J. Cancer. 1991; 63: 953-958.
12. Dixon RM. NMR studies of phospholipid metabolism in hepatic lymphoma. NMR Biomed. 1998; 11: 370-379. (Pubitemid 28547372)
13. Arias-Mendoza F, Smith MR, Brown TR. Predicting treatment response in non-Hodgkin's lymphoma from the pretreatment tumor content of phosphoethanolamine plus phosphocholine. Acad. Radiol. 2004; 11: 368-376.
14. Arias-Mendoza F, Payne GS, Zakian K, Stubbs M, Cruz-Lobo JG, Schwarz AJ, Dave A, Howe F, Maisey NR, Cunningham D, Poptani H, Smith MR, O'Connor OA, Pettengell R, Leach MO, Koutcher JA, Griffiths JR, Heerschap AH, Glickson JD. Treatment response predictor using 31P MRS for CHOP and R-CHOP therapy in diffuse large B-cell lymphoma. Proceedings of the 16th Annual Meeting ISMRM, Toronto, Canada, 2008; 768.
15. Gadian DG. NMR and Its Applications to Living Systems, (end edition). Oxford University Press: New York, 1996.
16. Schwarz AJ, Maisey NR, Collins DJ, Cunningham D, Huddart R, Leach MO. Early in vivo detection of metabolic response: a pilot study of 1H MR spectroscopy in extracranial lymphoma and germ cell tumours. Br. J. Radiol. 2002; 75: 959-966.
17. Schmitz JE, Kettunen MI, Hu DE, Brindle KM. 1H MRS-visible lipids accumulate during apoptosis of lymphoma cells in vitro and in vivo. Magn. Reson. Med. 2005; 54: 43-50.
18. Lee SC, Huang MQ, Nelson DS, Pickup S,Wehrli S, Adegbola O, Poptani H, Delikatny EJ, Glickson JD. In vivo MRS markers of response to CHOP chemotherapy in a human diffuse large B-cell lymphoma xenograft. NMR Biomed. 2008; 21: 723-733.
19. Lee SC, Delikatny EJ, Poptani H, Pickup S, Glickson JD. In vivo 1H MRS of WSU-DLCL2 human non-Hodgkin's lymphoma xenografts: Response to Rituximab and Rituximab plus CHOP. NMR Biomed. 2009; 22: 259-265.
20. Huang MQ, Pickup S, Nelson DS, Qiao H, Xu HN, Li LZ, Zhou R, Delikatny EJ, Poptani H, Glickson JD. Monitoring response to chemotherapy of non-Hodgkin's lymphoma xenografts by T(2)-weighted and diffusion-weighted MRI. NMR Biomed. 2008; 21: 1021-1029.
21. Bizzi A, Movsas B, Tedeschi G, Phillips CL, Okunieff P, Alger JR, Di Chiro G. Response of non-Hodgkin lymphoma to radiation therapy: early and long-term assessment with H-1 MR spectroscopic imaging. Radiology. 1995; 194: 271-276. (Pubitemid 24380964)
22. Mohammad RM, Wall NR, Dutcher JA, Al-Katib AM. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. Clin. Cancer. Res. 2000; 6: 4950-4956.
23. Pickup S, Lee SC, Mancuso A, Glickson JD. Lactate imaging with Hadamard-encoded slice-selective multiple quantum coherence chemical-shift imaging. Magn. Reson. Med. 2008; 60: 299-305.
24. He Q, Shungu DC, van Zijl PC, Bhujwalla ZM, Glickson JD. Single-scan in vivo lactate editing with complete lipid and water suppression by selective multiple-quantum-coherence transfer (Sel-MQC) with application to tumors. J. Magn. Reson. B. 1995; 106: 203-211.
25. Mori S, van Zijl PC. Diffusion weighting by the trace of the diffusion tensor within a single scan. Magn. Reson. Med. 1995; 33: 41-52.
26. Dyke JP, Zakian KL, Spees WM, Matei C, Chen Y, Mao X, Shungu DC, Koutcher JA. Metabolic response of the CWR22 prostate tumor xenograft after 20Gy of radiation studied by 1H spectroscopic imaging. Clin. Cancer Res. 2003; 9: 4529-4536.
27. Aboagye EO, Bhujwalla ZM, He Q, Glickson JD. Evaluation of lactate as a 1H nuclear magnetic resonance spectroscopy index for noninvasive prediction and early detection of tumor response to radiation therapy in EMT6 tumors. Radiat. Res. 1998; 150: 38-42.
28. Hall DE, Moffat BA, Stojanovska J, Johnson TD, Li Z, Hamstra DA, Rehemtulla A, Chenevert TL, Carter J, Pietronigro D, Ross BD. Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker. Clin. Cancer Res. 2004; 10: 7852-7859.
29. Liimatainen T, Hakumäki JM, Kauppinen RA, Ala-Korpela M. Monitoring of gliomas in vivo by diffusion MRI and 1H MRS during gene therapy-induced apoptosis: interrelationships between water diffusion and mobile lipids. NMR Biomed. 2009; 22: 272-279.
30. Bui T, Thompson CB. Cancer's sweet tooth. Cancer Cell. 2006; 9: 419-420.
31. Aboagye EO, Bhujwalla ZM, Shungu DC, Glickson JD. Detection of tumor response to chemotherapy by 1H nuclear magnetic resonance spectroscopy: effect of 5-fluorouracil on lactate levels in radiation-induced fibrosarcoma 1 tumors. Cancer Res. 1998; 58: 1063-1067.
32. Poptani H, Bansal N, Graham RA, Mancuso A, Nelson DS, Glickson JD. Detecting early response to cyclophosphamide treatment of RIF-1 tumors using selective multiple quantum spectroscopy (SelMQC) and dynamic contrast enhanced imaging. NMR Biomed. 2003; 16: 102-111.
33. Bhujwalla ZM, Glickson JD. Detection of tumor response to radiation therapy by in vivo proton MR spectroscopy. Int. J. Radiat. Oncol. Biol. Phys. 1996; 36: 635-639.
34. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324: 1029-1033.
35. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res. 1999; 59: 80-84.
36. Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res. 2001; 61: 3599-3603. (Pubitemid 32694969)
37. Ackerstaff E, Glunde K, Bhujwalla ZM. Choline phospholipid metabolism: a target in cancer cells? J. Cell Biochem. 2003; 90: 525-533.
38. Iorio E, Mezzanzanica D, Alberti P, Spadaro F, Ramoni C, D'Ascenzo S, Millimaggi D, Pavan A, Dolo V, Canevari S, Podo F. Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res. 2005; 65: 9369-9376.
39. Jordan BF, Black K, Robey IF, Runquist M, Powis G, Gillies RJ. Metabolite changes in HT-29 xenograft tumors following HIF-1alpha inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo. NMR Biomed. 2005; 18: 430-439.
40. Blankenberg FG, Katsikis PD, Storrs RW, Beaulieu C, Spielman D, Chen JY, Naumovski L, Tait JF. Quantitative analysis of apoptotic cell death using proton nuclear magnetic resonance spectroscopy. Blood. 1997; 89: 3778-3786.
41. Hakumaki JM, Poptani H, Sandmair AM, Yla-Herttuala S, Kauppinnen RA. 1H MRS detects polyunsaturated fatty acid accumulation during gene therapy of glioma: implications for the in vivo detection of apoptosis. Nat. Med. 1999; 5: 1323-1327.
42. Di Vito M, Lenti L, Knijn A, Iorio E, D'Agostino F, Molinari A, Calcabrini A, Stringaro A, Mescchini S, Arancia G, Bozzi A, Strom R, Podo F. 1H NMR-visible mobile lipid domains correlate with cytoplasmic lipid bodies in apoptotic T-lymphoblastoid cells. Biochim. Biophys. Acta. 2001; 1530: 47-66.
43. Al-Saffar NM, Titley JC, Robertson D, Clarke PA, Jackson LE, Leach MO, Ronen SM. Apoptosis is associated with triacylglycerol accumulation in Jurkat T-cells. Br. J. Cancer. 2002; 86: 963-970.
44. Milkevitch M, Shim H, Pilatus U, Pickup S, Wehrle JP, Samid D, Poptani H, Glickson JD, Delikatny EJ. Increases in NMR-visible lipid and glycerophosphocholine during phenylbutylate-induced apoptosis in human prostate cancer cells. Biochim. Biophys. Acta. 2005; 1734: 1-12.
45. Dubray B, Breton C, Delic J, Klijanienko J, Maciorowski Z, Vielh P, Fourquet A, Dumont J, Magdelenat H, Cosset JM. In vitro radiation-induced apoptosis and early response to low dose radiation in non-Hodgkin's lymphomas. Radiother. Oncol. 1998; 46: 185-191.
46. Delikatny EJ, Cooper WA, Brammah S, Sathasivam N, Rideout DC. Nuclear magnetic resonance-visible lipids induced by cationic lipophilic chemotherapeutic agents are accompanied by increased lipid droplet formation and damaged mitochondria. Cancer Res. 2002; 62: 1394-1400. (Pubitemid 34407798)
47. Garcia-Martin ML, Ballesteros P, Cerdan S. The metabolism of water in cells and tissues as detected by NMR methods. Prog NMR spectros. 2001; 39: 41-77.
48. Hamstra DA, Rehemtulla, Ross BD. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J. Clin. Oncol. 2007; 25: 4104-4109.
49. Mardor Y, Pfeffer R, Spiegelmann R, Roth Y, Maier SE, Nissim O, Berger R, Glicksman A, Baram J, Orenstein A, Cohen JS, Tichler T. Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. J. Clin. Oncol. 2003; 21: 1094-1100.
50. Kim S, Loevner L, Quon H, Sherman E,Weinstein G, Kilger A, Poptani H. Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck. Clin. Cancer Res. 2009; 15: 986-994.
51. Mellon EA, Lee SC, Pickup S, Kim S, Goldstein SC, Floyd TF, Poptani H, Delikatny EJ, Reddy R, Glickson JD. Detection of lactate with a Hadamard slice selected, selective multiple quantum coherence, chemical shift imaging sequence (HDMD-SelMQC-CSI) on a clinical MRI scanner: application to tumors and muscle ischemia. Magn. Reson. Med. 2009; 62: 1404-1413.
52. Lee SC, Mellon EA, Poptani H, Delikatny EJ, Glickson JD. Longitudinal study of 1H MRS of lactate upon treatment in a non-Hodgkin's lymphoma patient. Proceedings of the 17th Annual Meeting ISMRM, Honolulu, USA, 2009; 4205.
53. Baek HM, Chen JH, Nie K, Yu HJ, Bahri S, Mehta RS, Nalcioglu O, Su MY. Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy. Radiology. 2009; 251: 653-662.